Jordan Zwick
Chief Business Officer & Co-Founder Mirador Therapeutics
Jordan Zwick is an experienced leader in corporate strategy and business development in the biopharmaceutical sector. He served as strategic advisor to Prometheus Biosciences prior to its sale to Merck in June 2023. He was also a member of the board of directors and audit committee at Theratechnologies, Inc., where he played a substantial role in the sale of the company to Future Pak in 2025.Previously, Mr. Zwick held the role of SVP, Corporate Business Development and Investor Relations at Amarin Corp, where he closed multiple transactions for global partnering of the lead asset. He later became SVP, Chief Strategy Officer at InflaRx N.V., leading corporate strategy, business and corporate development, investor relations and contributing materially to the company’s public financings. He holds a B.A. and M.S. from Florida Atlantic University and an M.B.A from the University of San Francisco. He serves on the board of TruTechnologies, owned by LLR Partners, and is on the Advisory Board of the McKenna Life Sciences, Business and Entrepreneurship (MLSBE) Program at Arizona State University.
Seminars
- How much impact has AI/multi-modal data had on current approaches to drug discovery and translational drug development?
- How are we are validating new, and assessing novel versus de-risked targets?
- What type of clinical data would lead the field to reassess assumptions on a target?